[Edaily Reporter Yoo Jin-hee] #Wontech, a laser and energy-based medical solutions company, is expanding its reach to the African continent after obtaining medical device certification in South Africa for its cosmetic laser device, “Lavieen.”

Wontech announced on the 17th that it had received approval from the South African Department of Health for Lavieen as a device for non-invasive coagulation and non-ablative soft tissue treatment.

Lavieen is a low-power fractional laser device that utilizes a thulium laser with a wavelength of 1,927 nanometers (nm). It is characterized by its ability to deliver precise, non-ablative treatment from the epidermis to the dermis while minimizing damage to the skin’s surface. The device has secured product approvals in major global markets—including the U.S. Food and Drug Administration (FDA), as well as Brazil, Mexico, Saudi Arabia, China, Türkiye, and Australia—and has established itself as Wontech’s flagship export product.

This certification marks Wontech’s third approval in the South African market. Following the successful local launches of its vascular and pigment laser “V-Laser” and picosecond laser “Picocare450,” the company has sequentially secured approvals for its flagship product line—including the Lavian—thereby diversifying its local aesthetic medicine portfolio. Wontech’s strategy is to leverage local partnerships and medical professional networks—which possess distribution channels across the continent—to use South Africa as a springboard for entering the broader African market.

South Africa is considered the market with the most mature medical aesthetics industry infrastructure on the African continent. In particular, due to strong UV exposure and a dry climate, there is high local demand for treatments targeting pigmentation and skin aging (anti-aging). According to Grand View Research, a global market research firm, the South African medical aesthetics market is projected to expand from $223.3 million (approximately 330 billion won) in 2024 to $567.9 million (approximately 783 billion won) by 2033, driven by sustained annual growth.

A Wontech official stated, “Lavian is a device that has obtained approvals from stringent regulatory agencies around the world, including the FDA, and has been verified for global clinical references and safety,” adding, “With this certification, we have completed our global aesthetic medicine network, extending from the Americas, Europe, and Asia to Latin America and now the African continent.”